Atezolizumab (Tecentriq, Tecentriq Hybreza) coverage criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0128 alerts
Get alerted when Policy CC-0128 changes without checking for updates manually.
Monitor payer policy activity
Clinical prior authorization and coverage criteria for Tecentriq (atezolizumab) and Tecentriq Hybreza across multiple oncology indications, specifying clinical scenarios, combinations, and restrictions for Anthem members.
Add Tecentriq Hybreza step therapy and new step therapy table.
Remove age criteria for alveolar soft part sarcoma (ASPS) and update wording/formatting.
Add FDA indication for combination use with Zepzelca (lurbinectedin) in extensive-stage small cell lung cancer.
Modified non-squamous NSCLC criteria to allow use in actionable molecular markers and PD-L1 expression and allowed subsequent line or maintenance therapy.
Removed requirement for platinum therapy and ECOG in certain NSCLC updates and added cervical cancer criteria.
Added new indication for alveolar soft part sarcoma and later clarified do not approve criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.